Cargando…

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis

INTRODUCTION: The aim of this sub-study was to evaluate injection success of patients with rheumatoid arthritis (RA) and their caregivers administering the adalimumab (ADL) biosimilar, PF-06410293 (ADL-PF: adalimumab-afzb; Abrilada(®)/Amsparity(®)/Xilbrilada(®)) by prefilled pen (PFP) during the ope...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleischmann, Roy M., Bock, Amy E., Zhang, Wuyan, Godfrey, Charles M., Vranic, Ivana, Cronenberger, Carol, Dokoupilová, Eva
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127023/ https://www.ncbi.nlm.nih.gov/pubmed/35304684 http://dx.doi.org/10.1007/s40744-022-00439-8

Ejemplares similares

Randomized, Open‐Label, Single‐Dose, Parallel‐Group Pharmacokinetic Study of PF‐06410293 (adalimumab‐afzb), an Adalimumab Biosimilar, by Subcutaneous Dosing Using a Prefilled Syringe or a Prefilled Pen in Healthy Subjects
por: Cox, Donna S., et al.
Publicado: (2021)

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293
por: Fleischmann, Roy M, et al.
Publicado: (2021)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
por: Fleischmann, Roy M., et al.
Publicado: (2021)

A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis
por: Fleischmann, Roy M., et al.
Publicado: (2018)

Satisfaction and usability of the recombinant chorionic gonadotropin prefilled pen: a survey in Italy
por: Dallagiovanna, Chiara, et al.
Publicado: (2022)

Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects
por: Shin, Donghoon, et al.
Publicado: (2018)

Dose Accuracy, Injection Force, and Usability Assessment of a New Half-Unit, Prefilled Insulin Pen
por: Kappes, Christopher M., et al.
Publicado: (2017)

Assessing usability, label comprehension, pen robustness and pharmacokinetics of a self-administered prefilled autoinjector pen of methotrexate in patients with rheumatoid arthritis
por: Pachon, Jaime A, et al.
Publicado: (2014)

An evaluation of prefilled insulin pens: a focus on the Next Generation FlexPen(®)
por: Davis, Estella M, et al.
Publicado: (2010)

Prefilled syringes and usability of ophthalmic viscosurgical devices
por: Shiba, Takuya, et al.
Publicado: (2014)

Managing infertility with the follitropin alfa prefilled pen injector – patient considerations
por: Bühler, Klaus
Publicado: (2015)

Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience
por: Demary, Winfried, et al.
Publicado: (2014)

Prefilled pen versus prefilled syringe: a pilot study evaluating two different methods of methotrexate subcutaneous injection in patients with JIA
por: Roszkiewicz, Justyna, et al.
Publicado: (2020)

Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT‐P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects
por: Davidson, Antonia, et al.
Publicado: (2021)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Extension Study of PF‐05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis
por: Cohen, Stanley B., et al.
Publicado: (2018)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
por: Kapoor, Sanjiv, et al.
Publicado: (2019)

Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) in patients with advanced non-squamous non-small cell lung cancer
por: Li, Cheryl S. W., et al.
Publicado: (2019)

Correction to: AVT02: An Adalimumab Biosimilar
por: Kang, Connie
Publicado: (2022)

Navigating adalimumab biosimilars: an expert opinion
por: Abitbol, Vered, et al.
Publicado: (2023)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Similar Pharmacokinetics of the Adalimumab (Humira(®)) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE(®)-AI and VOLTAIRE(®)-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials
por: Ramael, Steven, et al.
Publicado: (2018)

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021)

Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab
por: Dickson, Sean R., et al.
Publicado: (2023)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Patient evaluation of the use of follitropin alfa in a prefilled ready-to-use injection pen in assisted reproductive technology: an observational study
por: Welcker, J Thomas, et al.
Publicado: (2010)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Consistency of Product Quality for SB5, an Adalimumab Biosimilar
por: Lee, JongAh Joanne, et al.
Publicado: (2023)

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
por: Francois, Fabien, et al.
Publicado: (2021)

User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study
por: Tauber, Maithé, et al.
Publicado: (2013)

Safety and Efficacy of Prefilled Liquid Etanercept-Biosimilar Yisaipu for Active Ankylosing Spondylitis: A Multi-Center Phase III Trial
por: Zhao, Dongbao, et al.
Publicado: (2021)

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
por: Velayudhan, Jyoti, et al.
Publicado: (2016)

FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension
por: Genovese, Mark C., et al.
Publicado: (2019)

Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
por: Lerch, Thomas F., et al.
Publicado: (2019)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1nf472d90kiai43co33vc94krt